Schonfeld Strategic Advisors’s Janux Therapeutics JANX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$617K	Buy	40,161 +27,822	+225%	+$403K	﹤0.01%	1722
2026 Q1	$172K	Sell	12,339 -33,114	-73%	-$454K	﹤0.01%	1780
2025 Q4	$627K	Buy	+45,453	New	+$1.07M	﹤0.01%	1310
2025 Q1	–	Sell	-109,500	Closed	-$5.86M	–	2351
2024 Q4	$5.86M	Sell	109,500 -39,855	-27%	-$2.11M	0.03%	452
2024 Q3	$6.79M	Sell	149,355 -93,176	-38%	-$4.05M	0.05%	427
2024 Q2	$10.2M	Buy	242,531 +89,810	+59%	+$4.22M	0.07%	343
2024 Q1	$5.75M	Buy	+152,721	New	+$3.33M	0.04%	591

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Schonfeld Strategic Advisors's JANX Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its Janux Therapeutics (JANX) stake by 225% in Q2 2026, buying an estimated $403K and bringing the position to 40,161 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Schonfeld Strategic Advisors first reported a position in JANX in Q1 2024 and has held it in 7 quarters since. The position peaked at $10.2M in Q2 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Schonfeld Strategic Advisors held 40,161 shares of Janux Therapeutics worth $617K as of Q2 2026.
Schonfeld Strategic Advisors bought 27,822 Janux Therapeutics shares in Q2 2026, an estimated $403K.
Janux Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1722 holding.
Schonfeld Strategic Advisors first reported a position in Janux Therapeutics in Q1 2024 and has held it in 7 quarters since.
Schonfeld Strategic Advisors's Janux Therapeutics position peaked at $10.2M in Q2 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.